Nasdaq

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo – – SER-109 was well ...
Seeking Alpha

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...
Yahoo Finance

Seres Therapeutics' SER-155 Reduces Infection, GvHD In Animal Study

Seres Therapeutics Inc (NASDAQ: MCRB) will present preclinical findings at the European Bone Marrow Transplantation (EBMT) Annual Meeting. The data suggest that SER-155 targets the host immune ...
Reuters

Seres Therapeutics announces key findings from SER-109 Phase 2 study analyses

* Seres - misdiagnosis of C. Difficile recurrent infection in some patients, suboptimal dosing contributed to reported SER-109 Phase 2 study outcome * Seres - saw statistically significant increase in ...